A 3-MONTH RANDOMIZED CONTROLLED TRIAL OF BIMATOPROST (LUMIGAN) VERSUS TIMOLOL/DORZOLAMIDE (COS - OPT

• 作 者: A.Coleman P.Bern-stein S.Whitcup
• 机 构: Jules Stein Institute/UCLA, CA,Allergan Inc., CA, USA,Allergan Inc., CA, USA
• 出 处: 国际眼科杂志
• 发表日期: 2003年01期
• 关键词: glaucoma intraocular prost Bern COS Coleman LUMIGAN OPT elusion baseline

Objective: To compare efficacy and safety of bimato-prost (Lumigan) QD vs timolol/dorzolamide (Cosopt) BID. Methods: Randomized, double-masked, multicenter 3-month clinical trial. 177 patients with glaucoma or ocular hypertension with uncontrolled intraocular pressure (IOPs between 22 and 34 mmHg) after at least 2 weeks of timolol 0.5% monotherapy were

Objective: To compare efficacy and safety of bimato-prost (Lumigan) QD vs timolol / dorzolamide (Cosopt) BID. Methods: Randomized, double-masked, multicenter 3-month clinical trial. 177 patients with glaucoma or ocular hypertension with uncontrolled intraocular pressure (IOPs between 22 and 34 mmHg) after at least 2 weeks of timolol 0.5% monotherapy were